Skip to main content
. 2022 May 12;1(3):100030. doi: 10.1016/j.cellin.2022.100030

Table 1.

Anti-H1N1 activity of N-substituted oseltamivir PROTACsa.

2.1.

a

The anti-H1N1 activity of all synthesized PROTACs was evaluated by plaque formation assays in MDCK cells. Oseltamivir phosphate (OSP) was used as the positive control. All data were acquired from at least three independent experiments. bEC50: effective concentration protecting 50% of cells from virus infection. cCC50: minimum concentration inducing 50% death of normal cells. dNA: no activity (EC50 > 50 μM).